Combined IGF1R and AXL inhibitors are required to block the PSC-induced tumor cell phosphoproteome—suggesting a Boolean “OR” axis between PSC IGF1/GAS6 and PDA pAKT (Figures 3F, 3G, and S4F; Data S1). This evidence concerns the gene IGF1R and neoplasm.